Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Total Liabilities: 2014-2025

Historic Total Liabilities for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $74.2 million.

  • Viridian Therapeutics, Inc.\DE's Total Liabilities rose 15.16% to $74.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.2 million, marking a year-over-year increase of 15.16%. This contributed to the annual value of $70.8 million for FY2024, which is 46.20% up from last year.
  • According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Total Liabilities is $74.2 million, which was up 10.44% from $67.2 million recorded in Q2 2025.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Total Liabilities ranged from a high of $74.2 million in Q3 2025 and a low of $16.0 million during Q4 2021.
  • Its 3-year average for Total Liabilities is $54.8 million, with a median of $56.3 million in 2024.
  • The largest annual percentage gain for Viridian Therapeutics, Inc.\DE's Total Liabilities in the last 5 years was 150.28% (2022), contrasted with its biggest fall of 1.85% (2022).
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Total Liabilities stood at $16.0 million in 2021, then spiked by 150.28% to $40.0 million in 2022, then rose by 20.92% to $48.4 million in 2023, then skyrocketed by 46.20% to $70.8 million in 2024, then climbed by 15.16% to $74.2 million in 2025.
  • Its Total Liabilities was $74.2 million in Q3 2025, compared to $67.2 million in Q2 2025 and $56.5 million in Q1 2025.